ATE192338T1 - Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen - Google Patents

Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen

Info

Publication number
ATE192338T1
ATE192338T1 AT93913731T AT93913731T ATE192338T1 AT E192338 T1 ATE192338 T1 AT E192338T1 AT 93913731 T AT93913731 T AT 93913731T AT 93913731 T AT93913731 T AT 93913731T AT E192338 T1 ATE192338 T1 AT E192338T1
Authority
AT
Austria
Prior art keywords
pct
natural killer
killer cells
pharmaceutical preparation
date
Prior art date
Application number
AT93913731T
Other languages
English (en)
Inventor
Kristoffer Hellstrand
Svante Hermodsson
Original Assignee
Maxim Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxim Pharm Inc filed Critical Maxim Pharm Inc
Application granted granted Critical
Publication of ATE192338T1 publication Critical patent/ATE192338T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT93913731T 1992-06-03 1993-06-03 Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen ATE192338T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201719A SE513429C2 (sv) 1992-06-03 1992-06-03 Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer
PCT/SE1993/000496 WO1993024144A1 (en) 1992-06-03 1993-06-03 PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK-CELLS), SAID PREPARATION CONTAINING INTERFERON-α AND HISTAMINE, SEROTONIN OR SUBSTANCES WITH CORRESPONDING RECEPTOR ACTIVITY

Publications (1)

Publication Number Publication Date
ATE192338T1 true ATE192338T1 (de) 2000-05-15

Family

ID=20386405

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93913731T ATE192338T1 (de) 1992-06-03 1993-06-03 Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen

Country Status (12)

Country Link
US (1) US5728378A (de)
EP (1) EP0652768B1 (de)
JP (1) JP2888259B2 (de)
AT (1) ATE192338T1 (de)
CA (1) CA2136952C (de)
DE (1) DE69328558T2 (de)
DK (1) DK0652768T3 (de)
ES (1) ES2147758T3 (de)
GR (1) GR3033894T3 (de)
PT (1) PT652768E (de)
SE (1) SE513429C2 (de)
WO (1) WO1993024144A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063373A (en) 1989-09-19 2000-05-16 Maxim Pharmaceuticals, Inc. Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
US6003516A (en) * 1992-06-03 1999-12-21 Maxim Pharmaceuticals, Inc. Method for treatment of cancer and infectious disease
JPH09502699A (ja) * 1993-03-26 1997-03-18 ベス、イスラエル、ホスピタル、アソシエーション バスピロン又はその誘導体の局部的及び全身投与に依る免疫反応性病体の治療
EP0775197A1 (de) 1994-08-08 1997-05-28 Maxim Pharmaceuticals, Inc. Verstärkte aktivierung von natürlicher killerzellen durch verwendung von einem fängern oder hemmern des wasserstoffperoxids
US6071942A (en) 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
AU778012B2 (en) * 1996-05-14 2004-11-11 Maxim Pharmaceuticals, Inc. Administration of histamine for therapeutic purposes
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
IL141627A0 (en) * 1998-08-24 2002-03-10 Maxim Pharm Inc Activation and protection of t-cells (cd4+and cd8+) using an h2 receptor agonist and other t-cell activating agents
EP0998923A1 (de) * 1998-10-30 2000-05-10 Basf Aktiengesellschaft Verwendung von 5-HT7 Rezeptoragonisten zur Behandlung oder Vorbeugung von Ischämien
US6403806B1 (en) 1998-12-23 2002-06-11 Maxim Pharmaceuticals, Inc. Synthesis of histamine dihydrochloride
US6498181B1 (en) 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6242473B1 (en) 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6153113A (en) * 1999-02-22 2000-11-28 Cobe Laboratories, Inc. Method for using ligands in particle separation
US6354986B1 (en) 2000-02-16 2002-03-12 Gambro, Inc. Reverse-flow chamber purging during centrifugal separation
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
WO2003035095A1 (en) * 2001-10-19 2003-05-01 Maxim Pharmaceuticals, Inc. Use of histamine to treat liver disease
EP1617838A4 (de) * 2003-04-25 2011-07-06 Mitsubishi Tanabe Pharma Corp Zusammensetzung für die orale verabreichung mit alkylendioxybenzol-derivaten
WO2005060960A2 (en) * 2003-12-11 2005-07-07 Maxim Pharmaceuticals, Inc. Use of histamine to treat bone disease
US20060002913A1 (en) * 2004-06-22 2006-01-05 Gehlsen Kurt R Use of histamine and related compounds to treat disorders affecting muscle function
EP1712634A1 (de) * 2005-04-13 2006-10-18 Wittycell SAS Verfahren zur Auswahl von effizienten antigen präsentierenden Zellen und ihre Anwendung in der Regulation der Immunität
SG166716A1 (en) 2009-05-14 2010-12-29 Hsiehs Biotech Singapore Pte Ltd Lycopene and resveratrol compositions for nk cell activation resulting in anti-neoplastic effect
US20160000777A1 (en) * 2013-02-21 2016-01-07 University Of Rochester Methods of using histamine receptor agonists and antagonists
CN115925920B (zh) * 2022-08-04 2023-07-25 瑞因细胞工程科技(广州)有限公司 一种基因增强型免疫细胞治疗肝硬化的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
EP0295317A1 (de) * 1987-06-16 1988-12-21 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Pharmazeutische Zusammensetzung zur Behandlung von Tumoren
US5215744A (en) * 1987-06-16 1993-06-01 Boehringer Ingelheim Gmbh Methods for the treatment of tumors
US4883661A (en) * 1987-10-09 1989-11-28 Daly John M Use of arginine as an lymphokine synergist
US5026544A (en) * 1988-02-16 1991-06-25 Board Of Reagents, The University Of Texas System Methods and compositions for inhibiting the growth of neoplastic cells

Also Published As

Publication number Publication date
CA2136952C (en) 2005-08-09
EP0652768A1 (de) 1995-05-17
JP2888259B2 (ja) 1999-05-10
ES2147758T3 (es) 2000-10-01
GR3033894T3 (en) 2000-11-30
AU672610B2 (en) 1996-10-10
WO1993024144A1 (en) 1993-12-09
DE69328558T2 (de) 2001-01-04
DE69328558D1 (de) 2000-06-08
JPH08502024A (ja) 1996-03-05
AU4366093A (en) 1993-12-30
SE9201719D0 (sv) 1992-06-03
US5728378A (en) 1998-03-17
SE513429C2 (sv) 2000-09-11
PT652768E (pt) 2000-09-29
CA2136952A1 (en) 1993-12-09
DK0652768T3 (da) 2000-08-07
EP0652768B1 (de) 2000-05-03
SE9201719L (sv) 1993-12-04

Similar Documents

Publication Publication Date Title
DE69328558D1 (de) Pharmazeutisches Präparat zur synergistischen Aktivierung natürlicher Killerzellen
RU2214418C2 (ru) Аналоги glp-1
EP0675708A1 (de) Pharmazeutische und dermokosmetische mittel enthaltend pferdecolostrum.
NO952744D0 (no) Cytokinbegrensende midler
ATE240721T1 (de) Dosiszusammensetzung mit modifizierter freigabe aus vielen einzelkomponenten
DE69333023D1 (de) 3-beta-hydroxylierte natürliche Steroidderivate enthaltende Arzneimittelzusammensetzungen und ihre Verwendung
PT99513A (pt) Processo para a preparacao de composicoes farmaceuticas contendo profarmacos de morfina para administracao topica por via transdermica
BR9916587A (pt) Aparelho e processo para preparar partìculas cristalinas de uma substância, população de partìculas, composição farmacêutica e partìculas cristalinas de 2,6-diamino-3-(2,3,5-triclorofenil)-pirazina
YU47543B (sh) Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
CZ64395A3 (en) Pharmaceutical composition containing antagonist of interleukin-1 receptor
PT86186A (en) Process for the preparation of benzimidazol derivatives and of pharmaceutical compositions containing the same
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
DE69506007D1 (de) Transdermales system zur gleichzeitigen verabreichung von mehreren wirkstoffen
DE59406938D1 (de) Pharmazeutische zubereitungen mit einem wirkstoff, der modifizierte amidingruppen enthält
DE69330752D1 (de) Unterdrückung proliferativer reaktionen und induktion von toleranz durch polymorphe typ ii-spezifische mhc allopeptide
AU3078892A (en) Human interleukin-8 analogs
DK0633763T3 (da) Kosmetiske eller farmaceutiske sammensætninger indeholdende deacylerede glycerophospholipider til topisk brug
NO933345D0 (no) Forbedrede retardsystemer for tidsforsinket frisetting avmedisinske og/eller biologiske aktive bestanddeler fra etdepot-baerermateriale
AU666422B2 (en) Novel bicyclic pyrimidine compounds, method for preparing same and pharmaceutical compositions containing said compounds
NO944214D0 (no) Farmasöytiske preparater for rektal administrering, inneholdende alkylsulfonamider som er HT1-agonister
NZ234451A (en) Benzofuran-substituted 2-imidazoline derivatives and pharmaceutical compositions
ATE169021T1 (de) Cephalostatin-analoga und ihre verwendung als antitumormittel
EP0348664A3 (de) Monoacetoacetine enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Tumoren
MX9303607A (es) Derivados de azabicicloheptano sustituidos, su obtencion y uso.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee